Search Cancer Clinical Trials
Active, not recruiting
To allow continuation of axitinib (AG 013736) treatment to patients experiencing clinical benefit in a closing axitinib trial
- Solid Tumors
- axitinib
- crizotinib
N/A
Interventional
Primary Outcome:
- Summary of Treatment Emergent Adverse Events (AEs) by Preferred Term Occurring In >20% Patients (All causality)
- Number of Participants With Treatment Emergent Adverse Events (AEs) (Treatment Related) of axitinib
- Number of Participants With Treatment Emergent Adverse Events (AEs) (Treatment Related) of crizotinib
- Summary of Treatment Emergent Serious Adverse Events (SAEs) by Preferred Term (All causality)
- Number of Participants With Treatment Emergent Serious Adverse Events (SAEs) (Treatment Related) of axitinib
- Number of Participants With Treatment Emergent Serious Adverse Events (SAEs) (Treatment Related) of crizotinib
52
March 7, 2003
- Gender: All
- Minimum age: 18 Years
- Maximum age: N/A
- Healthy volunteers: No
Pfizer
Pfizer
CONTINUING ACCESS TO THE TYROSINE KINASE INHIBITOR OF VEGFR-2, AG-013736 (A406) FOR PATIENTS PREVIOUSLY RECEIVING AG-013736 IN CLINICAL TRIALS
NCT00828919
Source: Clinicaltrials.gov. Through our founding membership in the Dana-Farber/Harvard Cancer Center, an NCI-designated Comprehensive Cancer Center, these clinical trials are conducted at the Massachusetts General Hospital Cancer Center and may be available at other partner institutions.